Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …

The discovery of recurrent gene fusions in a majority of prostate cancers has important
clinical and biological implications in the study of common epithelial tumours. Gene fusion …

Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …

Chromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the
oncogenic ETS transcription factor ERG occur in approximately 50% of prostate cancers, but …

TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer.
Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo …

The outbreak of the novel coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a serious public health …

Prostate cancer is a common heterogeneous disease, and most patients diagnosed in the
post prostate-specific antigen (PSA) era present with clinically localized disease, the …

The ERG gene is fused to TMPRSS2 in approximately 50% of prostate cancers (PrCa),
resulting in its overexpression. However, whether this is the sole mechanism underlying …

CONTEXT: In 2005, fusions between the androgen-regulated transmembrane protease
serine 2 gene, TMPRSS2, and E twenty-six (ETS) transcription factors were discovered in …

The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar
hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on …